ConductScience.org, home

Gene · 3811

KIR3DL1: killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. KIR3DL1: killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1. Genes, record 3811. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3811

On this page

Gene

Symbol
KIR3DL1
HGNC
Name
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1
HGNC
NCBI Gene ID
3811
NCBI Gene
HGNC ID
HGNC:6338
HGNC
Ensembl
ENSG00000167633
NCBI Gene
Aliases
AMB11, CD158E1, CD158e1/2, CD158e2, KIR, KIR3DL1/S1, NKAT-3, NKAT3, NKB1, NKB1B, cl-11, cl-2, nkat3
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P43629Killer cell immunoglobulin-like receptor 3DL144418Ensembl, GeneID, HGNC

Source UniProt

Patents54

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1450734P43629Espacenet
JP 2026004568 A2026-01-1450736P43629Espacenet
EP 4650780 A22025-11-1910843P43629Espacenet
JP 2025529142 A2025-09-042300P43629Espacenet
US 12371689 B22025-07-292300P43629Espacenet
JP 2025517970 A2025-06-1210843P43629Espacenet
US 12152253 B22024-11-263P43629Espacenet
JP 2024513880 A2024-03-2730P43629Espacenet
US 11858990 B22024-01-02169P43629Espacenet
KR 1020230165913 A2023-12-0530P43629Espacenet

1 to 10 of 54

See all 54 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,371

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleKIR3DL1 papersNewest fiscal year
P01CA111412NK cells, their receptors and cancer therapy392025
ZIABC010791Effects of genetic polymorphism in MHC, KIR, and related loci on human disease312025
P30CA008748Cancer Center Support Grant292025
P01CA065493Off-the-Shelf Immune Effector Cells for Hematological Malignancies262025
U01AI090905Insights Into Immune-Related Diseases Born from Population Genomics242025
U01AI069197Hematopoietic Stem Cell And Cord Blood Transplantation212025
T32AI007290Molecular and Cellular Immunobiology202025
P30CA077598Cancer Center Support Grant172025
ZIABC010792Molecular genetics and population studies of the KIR and HLA gene complexes172025
P30CA006927Comprehensive Cancer Center Program at Fox Chase142025

1 to 10 of 1,371Source NIH's project files

See all 1,371 nih grants

Papers2,526

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Clusterin expression and germinal center morphometry help distinguish idiopathic multicentric castleman disease from select lymphadenopathies.Front Immunol202642824315PubTator, text miningPubMed
Do FLT3 and KIR3DL1 converge on a common immune surveillance axis in treatment-free remission of chronic myeloid leukemia?Leukemia202642587024PubTator, text miningPubMed
High KIR diversity in Uganda and Botswana children living with HIV.Hum Immunol202642320219PubTator, text miningPubMed
Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers.Cancer Discov202642240229PubTator, text miningPubMed
Activating KIR3DS1: A key driver of KIR3DL1/HLA-Bw4-linked risk in CML.Hum Immunol202642034883PubTator, text miningPubMed
Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.Blood Adv202641995743PubTator, text miningPubMed
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.Leukemia202641888396PubTator, text miningPubMed
A Composite interaction Score: Prioritizing cell-cell interactions from single-cell RNA-seq with application to pre-menopausal epithelial barriers.J Adv Res202641875947PubTator, text miningPubMed
A genetic study of immunity in depression and interactions with childhood maltreatment.Transl Psychiatry202641856978PubTator, text miningPubMed
Thymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency in vitro.Virulence202641824632PubTator, text miningPubMed

1 to 10 of 2,526

See all 2,526 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/3811

GET https://conductscience.org/api/genes/v1/3811/patents?page=2